Recent Task Groups On the Use of MR in External Beam Radiotherapy: TG 284 and 294
Y Hu1*, C Glide-Hurst2*, K McGee3*, (1) Mayo Clinic Arizona, Phoenix, AZ, (2) University of Wisconsin, Middleton, WI, (3) Mayo Clinic, Rochester, MN
Presentations
MO-F-BRA-0 (Monday, 7/11/2022) 1:45 PM - 2:45 PM [Eastern Time (GMT-4)]
Ballroom A
The use of magnetic resonance imaging (MRI) to plan, deliver, monitor, and assess the efficacy of radiotherapy is an area of increasing interest and exploration. This has enabled a rapid expansion of MR-guided radiotherapy systems especially dedicated MR simulation platforms in Radiation Oncology (RO) in recent years. This emerging technology presents a new set of challenges and considerations that need to be addressed for safe and effective implementation. Recently, two AAPM task groups related to considerations for clinical implementation, optimization and QA (TG 284) and MR biomarkers in RO (TG 294), respectively, were published.
This educational session will review the two TG reports and cover acceptance testing, QA and staffing requirement pertaining to MR simulators. Optimization of dedicated radiation therapy specific protocols and workflows for radiotherapy planning and response assessment will be addressed. Finally, the current status of MR biomarkers in the context of RO, especially pertaining to therapeutic response assessment and adaptive replanning decisions be presented.
Our learning objectives are
1. Understand acceptance testing and QA pertaining to MR simulation and MR biomarkers
2. Learn safety, Staffing, equipment selection and optimization of simulation workflow for radiotherapy planning and response assessment studies
3. Understand the current status of MR biomarkers in radiation oncology
Funding Support, Disclosures, and Conflict of Interest: MSKCC has a master research agreement with Philips and Elekta healthcare
Keywords
Not Applicable / None Entered.
Taxonomy
Not Applicable / None Entered.
Contact Email